Dipexium Pharmaceuticals Inc. (NASDAQ:DPRX) Given Consensus Rating of “Strong Buy” by Brokerages
Dipexium Pharmaceuticals Inc. (NASDAQ:DPRX) has been given an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 12-month consensus price target of $27.25 for the company and are predicting that the company will post ($0.55) EPS for the current quarter, according to Zacks. Zacks has also assigned Dipexium Pharmaceuticals an industry rank of 93 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research upgraded shares of Dipexium Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, July 8th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/dipexium-pharmaceuticals-inc-nasdaqdprx-given-consensus-rating-of-strong-buy-by-brokerages.html
Dipexium Pharmaceuticals (NASDAQ:DPRX) traded up 0.47% during midday trading on Monday, hitting $15.01. 16,501 shares of the stock traded hands. The firm’s market cap is $156.07 million. Dipexium Pharmaceuticals has a 1-year low of $6.04 and a 1-year high of $17.75. The company has a 50-day moving average price of $13.83 and a 200-day moving average price of $11.43.
Dipexium Pharmaceuticals (NASDAQ:DPRX) last announced its earnings results on Thursday, August 4th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.02. Analysts predict that Dipexium Pharmaceuticals will post ($2.10) EPS for the current year.
Hedge funds have recently bought and sold shares of the company. Lombard Odier Asset Management USA Corp bought a new stake in Dipexium Pharmaceuticals during the second quarter valued at approximately $1,507,000. Raymond James & Associates bought a new stake in Dipexium Pharmaceuticals during the second quarter valued at approximately $312,000. Timpani Capital Management LLC boosted its stake in Dipexium Pharmaceuticals by 45.4% in the second quarter. Timpani Capital Management LLC now owns 64,124 shares of the company’s stock valued at $635,000 after buying an additional 20,014 shares in the last quarter. BlackRock Fund Advisors boosted its stake in Dipexium Pharmaceuticals by 19.6% in the second quarter. BlackRock Fund Advisors now owns 15,674 shares of the company’s stock valued at $155,000 after buying an additional 2,568 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Dipexium Pharmaceuticals by 8.7% in the second quarter. Vanguard Group Inc. now owns 158,297 shares of the company’s stock valued at $1,569,000 after buying an additional 12,670 shares in the last quarter. Institutional investors and hedge funds own 24.78% of the company’s stock.
Dipexium Pharmaceuticals Company Profile
Dipexium Pharmaceuticals, Inc is a late-stage pharmaceutical company. The Company is focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a first-in-class, broad spectrum, topical antibiotic. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dipexium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dipexium Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.